# Increasing Access to Medication-Assisted Treatment to Address the Opioid Epidemic: California's State Targeted Response

### Thomas E. Freese, Ph.D.

Co-Director, UCLA Integrated Substance Abuse Programs
Director, Pacific Southwest Addiction Technology Transfer Center
Adj Professor, UCLA David Geffen School of Medicine, Dept of Psychiatry

### Gloria Miele, Ph.D.

Learning Collaborative Coordinator, CA Hub and Spoke Project UCLA Integrated Substance Abuse Programs





## Disclosures

Dr. Freese and Dr. Miele do not have relevant financial relationships with commercial interests.





# Why do people take drugs?

#### To feel good

To have novel:

Feelings

Sensations

Experiences

AND

To share

them



#### To feel better

To lessen:

Anxiety

Worries

Fears

**Depression** 

Hopelessness

Withdrawal





### In other words:

A Major Reason People Take a Drug is they Like What It Does to Their Brain

Over time, this results in changes that lead to a disease process, but we have to change the message





## Substance Use Disorders, Like Other Diseases...

- > Are preventable
- > Are treatable
- Change biology
- > If untreated, can last a lifetime






#### **Science of Addiction**

Advances in medicine and scientific techniques have given researchers a clearer idea of what substance use disorders are using:

- Magnetic resonance imaging (MRI)
- Positron emission tomography (PET) scan
- Advanced genetic research












# Major Neurotransmitters Involved in SUD


- Dopamine
- Serotonin
- Norepinephrine
- GABA
- Glutamate





### Natural Rewards Elevate Dopamine Levels













# **Effects of Drugs on Dopamine Release**









Source: Shoblock and Sullivan; Di Chiara and Imperato


















#### **Dopamine D2 Receptors are Lower in Addiction**












# Cognitive and Memory Effects







# Partial Recovery of Brain Dopamine Transporters in Methamphetamine User After Protracted Abstinence



Source: Volkow, ND et al., Journal of Neuroscience 21, 9414-9418, 2001.





Substance Use Disorder is a chronic relapsing disorder similar to other chronic diseases such as diabetes, asthma, arthritis and cardiovascular disease.






# Why are we comparing SUD to these particular illnesses?

- No Doubt They Are Illnesses
- All Chronic Conditions
- Influenced by Genetic, Metabolic,
   Environmental and Behavioral Factors
- No Cures But Effective Treatments Are Available





#### Relapse Rates Are Similar for Drug Dependence and Other Chronic Illnesses



Source: McLellan, A.T. et al., JAMA, Vol 284(13), October 4, 2000.





### **Lessons from Chronic Care**

- Patient retention is critical
- Make treatment attractive
- Offer options/alternatives
- Increase monitoring/management







#### Every 20 minutes!!!




die every day from an **opioid overdose** (that includes prescription opioids and heroin).

Figure 1. Number of Injury Deaths by Drug Poisoning, Suicide, Homicide, Firearms, and Motor Vehicle Crashes in the United States, 1999-2014<sup>a,b</sup>



Source: Centers for Disease Control Prevention


# Overdose Deaths per 100,000 2003








# Overdose Deaths per 100,000 2014







### Opioid overdose deaths: Worst Case Scenario




Scenario 1: The opioid deaths forecast for 2027 is 93,613. The forecasted change is 183% since 2015 when it was 33,091. This curve assumes total drug overdoses climb at the same rate they have for decades. It's also based on the assumption opioid deaths keep making up roughly the same percentage of all drug deaths.

NATALIA BRONSHTEIN/STAT





#### Opioid overdose deaths: 10 projected scenarios.




The opioid deaths forecast for 2027 is 21,300. The forecasted change is -36% since 2015 when it was 33,091.

This curve assumes doctors prescribe fewer opioids, states embrace prescription drug monitoring programs, and insurers enact reforms to increase treatment access.





# Death Rates in Treated and Untreated Heroin Addicts



# Pharmacotherapies for addiction

- Methadone (agonist)
- Buprenorphine (partial agonist)
- Naltrexone (antagonist)





### Meanwhile, in Rhode Island

Screening and MAT in prison

61 % post-incarceration deaths

12% reduction in overdose deaths in the state's general population

Green, et al., JAMA Psychiatry. 2018;75(4):405-407





Home





**Get Naloxone Now** 







#### Save a Life

#### Learn how to respond to an overdose emergency

Get Naloxone Now is an online resource to train people to respond effectively to an opioid-associated overdose emergency. Get Naloxone Now advocates for widespread access to overdose education and training in how to administer naloxone, the life-saving antidote for opioidassociated overdose. Get Naloxone Now seeks to increase the number of lives saved by bystanders and professional first responders (police officers, firefighters and EMTs). Find out how you can contribute to reducing overdose deaths by accessing our online training modules.

# **CA Hub and Spoke MAT Expansion Project**





# What is the MAT Expansion Project?

- Two-year grant
- Projected to serve 20,892 Californians
- > Focuses on three specific projects:
  - 1. California Hub & Spoke System (CA H&SS)
  - 2. Tribal MAT Project
  - 3. California Society of Addiction Medicine (CSAM)
    Prevention and Treatment Activities





### **Short-Term Project Goals**

- Increase statewide utilization of buprenorphine
- Improve access to Narcotic Treatment Programs (NTPs) through the CA H&SS
- Increase MAT utilization in American Indian and Alaskan Native Tribal Communities through the Tribal MAT Project





### **Long-Term Project Goals**

- Save lives & foster recovery
- Address stigma and discrimination surrounding addiction
- Integrate addiction care into the greater health care system
- Development of innovative and sustainable practices, processes, and relationships





# California Hub & Spoke System





# **No Wrong Door**







### **CA Hub & Spoke System**

- Based on the Vermont Hub & Spoke Model
- ➤ Harnesses the strengths of specialty methadone NTPs and skills of physicians and advanced practice clinicians who prescribe buprenorphine in officebased settings.
- ➤ NTPS are the only entities that are allowed by federal law to provide methadone treatment for an OUD.





#### Hubs

- NTPs act as "Hubs," and serve as the regional consultants and subject matter experts on opioid dependence and treatment
- Provide care to clinically complex buprenorphine patients
- Manage buprenorphine inductions
- Support Spokes that need clinical or programmatic advice





#### **Spokes**

- Spokes may be (1) a federally waivered prescriber, or (2) one or more federally waivered prescribers and a MAT team.
- Provide ongoing care for patients with milder addiction (managing induction and maintenance) and for stable patients on transfer from a Hub
- > Monitor adherence to treatment
- Coordinate access to recovery supports
- Provide counseling





#### **Required Services**

Professional medical, social work, & mental health services, onsite or by referral

Access to FDA approved MAT for an OUD

Access to subject matter expertise on opioid dependence and treatment for Spokes

HIV and HCV testing and referral to services

Case management

Counseling

Naloxone and training

Local access to maternal addiction treatment

Recovery and/or peer support services

Use of the OBOT Stability Index and the Treatment Need Questionnaire tool





### **Hub and Spoke MAT Team**

#### **Educator/Panel Manager**

- Responsible for:
  - Prescription Management
  - Call back procedure, counting films, calling pharmacies
  - Management of drug testing
  - Coordination of medical services with buprenorphine prescriber
  - Help the physician manage the panel of patients and educa.

#### **Case Manager**

#### •Responsible for:

- Brief counseling or referral to more intensive services
- Group counseling
- Some clinical case management
- Intake of stable patients from Hub to Spoke
- Referrals to Hub for unstable patients
- Coaching to prescribers in managing patients' clinical stability





### **Hub and Spoke Interaction**

- ➤ Patients can move between the Hub and Spoke based on clinical severity and need
- ➤ If patients begin services at a Spoke and need more care, they can transition to the Hub. If the patient starts at the Hub and needs less care, they can transition to the Spoke

HUB ← SPOKE





### **CA H&SS Implementation**




- \$78 million allocated to CA H&SS treatment services
- > 19 Hubs
- ➤ Over 85 Spokes covering 30+ counties. This includes 7 of the 10 counties with highest opioid overdose rates

http://www.dhcs.ca.gov/individuals/Documents/CA\_HSS\_Awards\_7.21.17.pdf





#### **CA H&SS Governance and Partners**



**Advisory Group:** Implementation & evaluation experts, CA H&SS participants, community members, DHCS representatives, CSAM, California Health Care Foundation (CHCF)





#### **CA H&SS Results To Date**

#### **Successes**

- Strong support from law enforcement
- Building relationships with local health plans
- Coordination with Opioid Coalitions
- Interest among community/stakeholders
- Over 100 spokes
- More buprenorphine prescribers

#### Challenges

- Hiring qualified providers/staff
- MD mentors and consultants
- Stigma against MAT
- Transportation for patients
- Providing services for the criminal justice population
- Finding spokes in rural areas





#### What's Next?

- Spoke development
- More providers, more treatment
- Pain and addiction conferences
- Prescriber facilitation mentoring and consultation
- ED Bridge
- Preliminary data





### Questions???

Thomas E Freese, PhD: <a href="mailto:tfreese@mednet.ucla.edu">tfreese@mednet.ucla.edu</a>
Gloria Miele, PhD: <a href="mailto:gmiele@mednet.ucla.edu">gmiele@mednet.ucla.edu</a>

Pacific Southwest ATTC: <a href="http://www.psattc.org">http://www.psattc.org</a>
Hub and Spoke: <a href="http://uclaisap.org/ca-hubandspoke">http://uclaisap.org/ca-hubandspoke</a>

Join our listserve! Email kimberlyvalencia@mednet.ucla.edu



